Liver Cancer  >>  Lipotecan (TLC388)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipotecan (TLC388) / Taiwan Liposome Company
NCT02267213: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Terminated
2
29
RoW
Lipotecan, Lipotecan, TLC388
Taiwan Liposome Company
Hepatocellular Carcinoma
07/15
07/15
NCT01425996: A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Terminated
1/2
3
RoW
Lipotecan® (TLC388), Lipotecan (TLC388)
Taiwan Liposome Company
Carcinoma, Hepatocellular
10/14
10/14

Download Options